Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000110

General Counsel sold 9,000 shares at an average $78.53 ($706,735)

  • General Counsel acquired 9,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Quinlan Paul T General Counsel 2026-10-20 Option exercise 10b5-1 +9,000 $7.80 $70,200 38,995 D: show line 1 in the form
Quinlan Paul T General Counsel 2026-10-20 Sale 10b5-1 −400 $74.90 $29,960 38,595 D: show line 2 in the form
Quinlan Paul T General Counsel 2026-10-20 Sale 10b5-1 −500 $76.12 $38,059 38,095 D: show line 3 in the form
Quinlan Paul T General Counsel 2026-10-20 Sale 10b5-1 −1,000 $77.21 $77,205 37,095 D: show line 4 in the form
Quinlan Paul T General Counsel 2026-10-20 Sale 10b5-1 −4,100 $78.79 $323,037 32,995 D: show line 5 in the form
Quinlan Paul T General Counsel 2026-10-20 Sale 10b5-1 −3,000 $79.49 $238,474 29,995 D: show line 6 in the form
Open-market sales · 9,000 sh · avg $78.53 · $706,735

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Quinlan Paul T General Counsel 2026-10-20 Option exercise · Employee Warrant (right to buy) 10b5-1 −9,000 70,996 D: show line 7 in the form
Loading xslF345X06/form4.xml…